Biography
Arie S. Belldegrun is a trail‑blazing urologic‑oncologist‑turned‑biotech entrepreneur whose company‑building spree—from Agensys and Cougar to Kite Pharma—helped usher in the first FDA‑approved CAR‑T therapy and led to Kite’s $11.9 billion sale to Gilead Sciences.After that landmark exit, he co‑founded Allogene Therapeutics and still serves as its Executive Chairman, steering the next wave of off‑the‑shelf (allogeneic) CAR‑T cell products toward the clinic.Beyond Allogene, Belldegrun deploys capital through Bellco Capital, Two River, Symbiotic Capital, Vida Ventures, and the real‑estate venture Breakthrough Properties, nurturing a constellation of startups that translate science into patient impact.Over three decades on UCLA’s faculty, he has authored 500‑plus scientific papers, mentored a generation of physician‑scientists, and kept patient benefit at the center of every deal—cementing his reputation as one of precision medicine’s most influential builders.

Biography
Dr. Kiran Kaur Khush is a board-certified, fellowship-trained heart failure cardiologist at Stanford Health Care. Dr. Khush is also a professor in the Department of Medicine, Division of Cardiovascular Medicine at Stanford University School of Medicine. Dr. Khush specializes in caring for patients with advanced heart failure and those needing a heart transplant or mechanical circulatory support. She is dedicated to delivering patient-centered, compassionate care and improving quality of life for people with heart failure. Dr. Khush’s research interests include developing evidence-based guidelines for evaluating and accepting donor hearts for transplantation. She also studies novel ways to monitor for and prevent early and long-term complications after heart transplantation. Dr. Khush has coauthored more than 200 articles in peer-reviewed journals, including Circulation, Journal of the American College of Cardiology, Science Translational Medicine, and The Lancet. She has also presented to her peers at international and national meetings, including annual sessions of the International Society for Heart and Lung Transplantation (ISHLT) and the American Society of Transplantation. Throughout her career, Dr. Khush has been an active member of the ISHLT and has served on many of the organization’s committees.

Biography
Dr. Sadovsky is the Executive Director of Magee Women's Research Institute, the Elsie Hilliard Hillman Chair of Women's Health Research, Distinguished Professor of OBGYN, Microbiology and Molecular Genetics, and Associate Dean, Women's Health Research and Reproductive Sciences, University of Pittsburgh. He is board certified in obstetrics and gynecology (Washington University), and maternal-fetal medicine (UCSF). His NIH-funded research focuses on feto-placental development and molecular mechanisms underlying placental function, aiming to better understand early human development and pregnancy health. He is a member of the National Academy of Medicine and the Association of American Physicians. He has served as president of the Society for Reproductive Investigation, on the Councils for NIHNICHD and the March of Dimes, and currently serves on the NIH Advisory Committee on Research in Womens Health. In 2013, he was awarded the Cozzarelli Prize in Biomedical Science from the National Academy of Sciences.

Biography
Iwijn De Vlaminck trained in applied physics (Ph.D., KULeuven), single molecule biophysics (postdoc, TUDelft) and precision medicine (HHMI research associate, Stanford University). His most recent research has led to the development of sensitive blood tests to diagnose organ transplant rejection, already widely used, the Karius blood test to screen for infection from blood, used in more than 400 US hospitals, RNA liquid biopsy technologies to monitor inflammatory disease, technologies to spatially map RNA in tissues, and highly multiplexed imaging methods to map the biogeography of the human microbiome. He is an elected fellow of the American Institute of Medical and Biological Engineering and a recipient of the NIH New Innovator and NIH MERIT awards. He is a co-founder of Kanvas Biosciences and Romix Biosciences.

Biography
Charles Chiu, M.D. Ph.D. is a Professor at UCSF, Director of the UCS-FAbbott Viral Diagnostics and Discovery Center (VDDC), and Associate Director of the UCSF Clinical Microbiology Laboratory. Chiu currently leads a translational research laboratory focused on clinical metagenomic sequencing assay development for infectious diseases and genomic investigation and surveillance of emerging pathogens, including the SARSCoV2 coronavirus. He also uses RNASeq transcriptome profiling to develop predictive models using machine learning for host response based diagnosis of COVID19 and other infections. Chius work is supported by funding from the National Institutes of Health (NIH), Department of Defense, US Centers for Disease Control and Prevention (CDC), philanthropy, and the California Initiative to Advance Precision Medicine. He has authored more than 100 peer reviewed publications (20 on COVID19), holds over 15 patents and patent applications, and serves on the scientific advisory board for Mammoth Biosciences, Danaher Dx, Biomesense, and Flightpath.

Biography
Dr. Joe DeRisi is a professor of biochemistry and biophysics at UCSF and President at the Chan Zuckerberg Biohub SF, a nonprofit research institute affiliated with UCSF, UCB, and Stanford. Dr. DeRisi specializes in infectious diseases, including viral, fungal, and parasitic microbes, in addition to autoimmune syndromes in humans. He is a member of the NAS, the NAM, and the American Academy of Arts and Sciences.

Biography
Dr. Minnie M. Sarwal is an adult and pediatric trained transplant nephrologist who heads the kidney pancreas transplant program at UCSF for transplantation of patients with Type 1 Diabetes and renal failure. She has spearheaded new diagnostics for precision medicine to personalize diagnosis of transplant rejection. Her lab has been consecutively funded by the NIH for 30 yrs and leads in computational drug repuprosing and population scale EHR analysis to improve outcomes for chronic disease. Sarwal is trained in India and the UK, competing her MD in India and advanced cliical training at Guys Hospital, London and Addenbrooke's Hospital in Cambridge. She earned her doctorate in molecular genetics at the University of Cambridge under her mentor Nobel Laureate Sydney Brenner. Sarwal is an exited enterpreneur from Stanford and continues to do pivotal work to produce commercially available tests and new compunds for organ transplant rejection and chronic mutli-organ disease

Biography
Dr. Joe DeRisi is a professor of biochemistry and biophysics at UCSF and President at the Chan Zuckerberg Biohub SF, a nonprofit research institute affiliated with UCSF, UCB, and Stanford. Dr. DeRisi specializes in infectious diseases, including viral, fungal, and parasitic microbes, in addition to autoimmune syndromes in humans. He is a member of the NAS, the NAM, and the American Academy of Arts and Sciences.

Biography
Duncan MacCannell is the Director of the Office of Advanced Molecular Detection (OAMD) at the National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) at the CDC. He has been instrumental in using emerging next generation sequencing technologies to transform infectious disease public health, leading to the establishment of the Advanced Molecular Detection (AMD) Program in 2014. He has guided the program's development and application of sequencing and high performance computing to public health priorities such as detecting and responding to outbreaks and identifying emerging infectious threats. During the pandemic response, Dr. MacCannell established the CDC SPHERES Consortium, which tracks the spread and evolution of SARSCoV2, the virus that causes COVID19. He leads the consortium's efforts to monitor the emergence and spread of new SARSCoV2 variants, which is critical for informing public health decision making, tracking the evolution of infectious diseases and to inform public health policy

Biography
Bruce Quinn MD PhD is an expert on health reform, innovation, and Medicare policy. A pathologist by training, he has worked on a wide range of federal health policy issues ranging from biopharma to genomics. After a career in academic medicine, he became a successful physician executive at Accenture, serving clients in both the biopharma and payer industries. For five years, he was the regional Medicare medical director for California, making decisions on a wide range of emerging technologies. Since 2008, he has been a full time life sciences strategy consultant at several major Washington-based policy firms. Since 2017, Dr. Quinn manages his own medtech and biopharma consulting practice based in Los Angeles and San Francisco, Bruce Quinn Associates LLC.

Biography
Independent investigator with an active research laboratory for >25 years, focusing on discovering pathogenic pathways and bringing therapies to patients in the areas of hypertensive disorders of pregnancy and kidney diseases Research activities are vertically integrated, ranging from molecular and cell biological studies to animal models, epidemiological studies and frist-in-class human clinical trials >350 publications (H index =133) & research supported by HHMI, NIH, AHA, Gates foundation and industry; 15 issued patents in biomedicine Co-director of NIH training grant for Kidney, Urology and Hematology at UCLA/Cedars-Sinai Received multiple scientific recognition awards (Established Investigator Award - AHA, Chesley Award - International Society for the Study of Hypertension in Pregnancy, Outstanding Investigator Award - American Federation of Medical Research, Jean Hamburger Prize- ISN) Inducted to American Society for Clinical Investigation (ASCI) and Association of American Physicians (AAP) Trained >50 graduate and post-doctoral fellows in basic and translational research. Associate Editor-Hypertension and Editorial board of numerous medical Journals (JCI, JASN, Hypertension in Pregnancy) 12 endowed lectureships and > 200 invited lectures throughout the world

Biography

Biography
Dr. Bien-Willner is the Medical Director of the MolDX program at Palmetto GBA, a Medicare Administrative Contractor (MAC). He is a leader in the Precision Medicine space and practices as a Board-certified Anatomic Pathologist and Molecular Genetic Pathologist. Throughout his career, he has been active in research, development, and advancement of molecular diagnostic services, specifically next generation sequencing. He hasworkedclosely with clinicians to develop clear clinical diagnostic andtreatmentpathways directing Precision Medicine programs for communitycancercenters.Dr. Bien-Willner received his MD and PhD degrees fromBaylorCollege of Medicine, with a PhD in Human Molecular Genetics.Hecompletedhis residency, fellowship, and attained a faculty appointment atWashingtonUniversity in St. Louis prior to leadership roles in laboratoryand biotechcompanies before joining Palmetto GBA.

Biography

Biography
Dawn Cardeiro, M.S., is a Market Access Strategy Director at Roche Diagnostics, where she develops U.S. strategies to advance patient access to innovative diagnostics. Her career spans over three decades in clinical, advocacy, and commercial roles in precision medicine, including positions at North Central Bronx Hospital, Baystate Medical Center, Point32Health, Myriad Genetics, and Foundation Medicine. Dedicated to shaping payer policy and expanding access to diagnostics, Dawn serves on the board of the Access to Comprehensive Genomic Profiling Coalition (ACGP) and previously served on the board of directors for the Personalized Medicine Coalition (PMC). She holds a B.S. in Chemistry from Fairfield University and an M.S. in Human Genetics from Sarah Lawrence College, where she trained as a genetic counselor. By combining her clinical roots and deep technical foundation with extensive industry expertise, Dawn effectively navigates complex health systems to improve patient outcomes.

Biography

Biography
Alexandre Loupy is an internationally recognized physician-scientist who has transformed how transplant rejection and long-term graft survival are characterized and predicted. He is at the head of the Paris Institute for Transplantation & Organ Regeneration, where he has built large, deeply characterized cohorts integrating clinical, biological, immunologic, histologic, and transcriptomic data. He led the development of iBox, a prediction system that combines kidney function, proteinuria, donor-specific antibodies, and biopsy findings to estimate an individual patient's risk of kidney-allograft loss. The system was developed and validated in 7,557 recipients across 10 centers in Europe and North America and confirmed in three randomized clinical trials. It has received regulatory qualification in Europe and a favorable FDA qualification opinion for transplant clinical trials. Loupy has also applied machine learning and molecular profiling to identify distinct rejection phenotypes and improve transplant diagnostics. His work extends beyond kidney transplantation to heart-transplant rejection and pig-to-human xenotransplantation.

Biography
Alexandre Loupy is an internationally recognized physician-scientist who has transformed how transplant rejection and long-term graft survival are characterized and predicted. He is at the head of the Paris Institute for Transplantation & Organ Regeneration, where he has built large, deeply characterized cohorts integrating clinical, biological, immunologic, histologic, and transcriptomic data. He led the development of iBox, a prediction system that combines kidney function, proteinuria, donor-specific antibodies, and biopsy findings to estimate an individual patient's risk of kidney-allograft loss. The system was developed and validated in 7,557 recipients across 10 centers in Europe and North America and confirmed in three randomized clinical trials. It has received regulatory qualification in Europe and a favorable FDA qualification opinion for transplant clinical trials. Loupy has also applied machine learning and molecular profiling to identify distinct rejection phenotypes and improve transplant diagnostics. His work extends beyond kidney transplantation to heart-transplant rejection and pig-to-human xenotransplantation.